Missax Bad Medicine !full! • No Login

| Indication | Evidence (published) | Regulatory approval | |------------|----------------------|----------------------| | Seasonal allergic rhinitis | 2 small Phase II trials (n = 45, 52) – modest reduction in TNSS (Total Nasal Symptom Score) vs. placebo (p = 0.04). | None | | Mild‑to‑moderate persistent asthma (as adjunct) | 1 open‑label pilot (n = 30) – improvement in FEV₁ + 8 % (non‑significant). | None | | Chronic urticaria (off‑label) | Case series (n = 12) – symptom relief in 5 patients. | None | | No Phase III, pivotal, or confirmatory trials have been published in peer‑reviewed journals. Most data stem from company‑sponsored abstracts or conference posters. |

💬 If you’re looking for a tune that’s both a cure and a curse, press play. Just don’t blame us if you can’t shake it off later. 🎧 missax bad medicine

| Parameter | Assessment | |-----------|------------| | | Limited and low‑quality evidence; modest symptomatic relief for allergic rhinitis only. | | Safety | Multiple serious organ toxicities; high signal for liver and cardiac events. | | Alternatives | Numerous FDA‑approved antihistamines (e.g., cetirizine, fexofenadine) and leukotriene modifiers with robust safety records. | | Overall | Negative – The marginal benefit does not outweigh the documented risks. The drug’s risk profile is unacceptable for routine clinical use. | | Indication | Evidence (published) | Regulatory approval